333 results about "Tumor immunity" patented technology

The present invention relates to the field of cancer immunotherapy. Specifically, the present invention relates to the effect of an intestinal-specific strain Anaerostipes caccae ibiome007 on anti-tumor immunity, and provides a method for improving the tumor immunotherapy response rate of patients.

The invention discloses an application of a small molecular compound LZ-A4 in preparation of a preparation or a medicine for treating malignant tumors. The chemical formula of the small molecule compound LZ-A4 is C19H11Cl2N3O3S, and the small molecule compound LZ-A4 can promote degradation of LGMN in malignant tumor cells, inhibit proliferation of tumor cells and inhibit polarization of macrophages to M2 type. The research on a colorectal cancer mouse transplantation tumor model proves that the development of the colorectal cancer can be effectively inhibited by single treatment of the LZ-A4, and the volume of the tumor can be further reduced after the LZ-A4 is combined with a clinical first-line chemotherapeutic drug Oxaliplatin for the colorectal cancer. Meanwhile, the LZ-A4 can inhibit M2 type polarization of macrophages in a tumor microenvironment in vivo, promote infiltration of cytotoxic T cells, remodel the tumor microenvironment and activate anti-tumor immunity. In addition, the A4 has good toxic and side effects, and does not cause further reduction of the body weight of the mouse after being combined with chemotherapeutic drugs.

The invention discloses a preparation method and application of a dual-targeting carrier-free delivery system for enhancing anti-tumor immunity of NKT cells, Lys-alpha-GalCer is used as a raw material, and two molecules of LGC are connected through a disulfide bond to synthesize an amphiphilic LGC-SS-LGC micromolecule prodrug; the LGC-SS-LGC micromolecule prodrug is prepared into vesicles internally loaded with an NKT cell antigen presenting molecule CD1d and externally modified with polysarcosine through electrostatic adsorption through a film dispersion-probe ultrasonic method, finally a CD1d / LGC-SS-LGC / PSar dual-targeting carrier-free delivery system is formed, and the dual-targeting carrier-free delivery system can be used for liver cancer treatment after intravenous administration. In addition, the compound can be used for preparing a preparation for enhancing NKT cell Th1 type immune response. The dual-targeting carrier-free delivery system prepared by the invention can directly or indirectly enhance the anti-tumor immune effect of the NKT cells, and has a dual-synergistic effect.

The invention belongs to the technical field of biological detection, and provides a multiple cell factor detection kit in tumor immunity and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture antibody is prepared by coupling a biotinylated antibody with a fluorescent microsphere coated with biotin to obtain a capture antibody coupled with a fluorescent encoding microsphere, and the detection antibody is prepared by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody to obtain a fluorescent labeled antibody; the mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect various cell factors, the sample dosage is only 25 microliters, the kit is suitable for immune monitoring of iron overload and other chronic inflammation models, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of being high in throughput, wide in linear range and high in stability.

The present invention provides an animal Bifidobacterium lactis subsp. lactis for enhancing anti-tumor immunity of lung cancer and an application thereof. The present invention separates and preserves animal Bifidobacterium lactis subsp. lactis SDZL01 for enhancing anti-tumor immunity of lung cancer, and names it as animal Bifidobacterium lactis subsp. lactis SDZL01 strain. Animal Bifidobacterium lactis subsp. lactis has been deposited in the General Microbiological Center of China Microbiological Culture Collection Administration on November 18, 2024, and its preservation number is Bifidobacterium lactis subsp. lactis CGMCC No. 32692. Animal Bifidobacterium lactis subsp. lactis or its metabolite indole‑3‑acetic acid can be used to regulate the immune microenvironment of NSCLC or enhance immunotherapy. Animal Bifidobacterium lactis subsp. lactis can enhance anti-tumor immunity and can be used to prepare products that enhance immunotherapy of lung cancer. Animal Bifidobacterium lactis subsp. lactis can improve the response rate of cancer immunotherapy population and expand the population of tumor patients who benefit from cancer immunotherapy.

The invention discloses a tumor nano vaccine (BAPs) of bionic autophagosome as well as a preparation method and application thereof, and the vaccine effectively stimulates anti-tumor immunity by precisely fusing a neoantigen derived from the autophagosome and an immunologic adjuvant targeted lymph node. The BAPs with the redox response characteristic promote the vaccine to be opened in antigen presenting cells, so that an adjuvant and an antigen are exposed, and a strong immune response is stimulated. The BAPs can excite wide T cell reactions, and finally, more than 70% of established tumors are effectively eliminated. BAPs vaccination initiates a lasting T cell reaction and provides powerful protection, all mice are protected in tumor recurrence challenge, and the tumor incidence rate is significantly reduced by nearly 90%. In addition, the BAPs and a checkpoint inhibition therapy have a synergistic effect, and growth of breast cancer with poor immunogenicity is inhibited. The BAPs nano vaccine provides an efficient strategy with clinical transformation potential to enhance the strong immune response of personalized cancer immunotherapy.

The invention relates to the technical field of antitumor drugs, in particular to a Ru (II) complex and a preparation method and application thereof, and the Ru (II) complex has a structure as shown in a formula I. The ruthenium (II) complex has excellent anti-tumor activity, can induce tumor cells to generate ICD death, can be quickly positioned in an endoplasmic reticulum, causes the intracellular active oxygen level to rise, blocks the cell cycle in the S phase, and finally induces the tumor cells to generate pyroptosis. More importantly, MCF-7 cells can be caused to generate endoplasmic reticulum stress, so that an ICD effect is triggered, DC in tumor tissues is increased, chemotaxis of effector T cells in the tumor tissues is improved, and meanwhile, the number of Treg cells with an immunosuppression effect can be reduced, so that tumor immunity of an organism is activated. In addition, the Ru (II) complex can activate a cGAS-STING pathway, the proportion of CD8 + T cells is increased, and the anti-tumor immunocompetence is further improved.

The invention provides a preparation method of a two-dimensional nanobelt. The two-dimensional manganese risedronate nanobelt (RMn-NBs) is prepared from Mn < 2 + > and risedronate sodium by using a coordination self-assembly technology. The raw materials are cheap and easy to obtain, and the preparation process is simple, easy to operate and good in controllability. The two-dimensional risedronate manganese nanobelt can inhibit a hypoxia-inducible factor / vascular endothelial growth factor (HIF-1alpha / VEGF) through risedronate sodium so as to enhance the radiotherapy effect; meanwhile, Fenton-like reaction of Mn < 2 + > is utilized to amplify oxidative stress mediated by radiotherapy, a GMP-AMP synthetase stimulating factor (cGAS-STING) pathway of an interferon gene ring is synchronously activated, secretion of I-type interferon is promoted, ICD (immunogen cell death) is effectively induced, and the immunogen cell death rate is increased. And the effects of CD8 + T cell dependent systemic anti-tumor immunity and checkpoint blocking immunotherapy on primary and metastatic tumors are greatly enhanced. The RMn-NBs is used as a novel nanoscale in-situ radiotherapy vaccine, and has good biocompatibility and treatment effect.

The invention belongs to the technical field of biological medicines, discloses a fusion protein as well as a preparation method and application thereof, and particularly discloses a fusion protein which comprises a DDX60 functional structural domain and a tumor-targeted cell-penetrating peptide. The invention provides a fusion protein, the fusion protein has tumor targeted cell penetrability and can activate anti-tumor immunity, and the fusion protein can directly send a DDX60 functional structure domain into tumor cells and maintain the stability of dsRNA; meanwhile, the protein can improve the sensitivity of other anti-tumor immunotherapies by activating the autoimmunity of a body, a new thought is provided for the development of anti-cancer targeted drugs, the efficiency and the application range of the existing anti-tumor immunotherapies are expanded, and the protein has important significance in tumor treatment.

The invention discloses a polyethylene glycol modified gold and manganese dioxide nano particle and a preparation method and application thereof, and belongs to the technical field of biological medicine, the polyethylene glycol modified gold and manganese dioxide nano particle (GMCN and PEG) has good biocompatibility under neutral physiological conditions, can relieve tumor hypoxia and increase generation of active oxygen in acidic TME, and has a good anti-tumor effect. The radiotherapy sensitivity is improved; and immune cell death is induced. Meanwhile, a cGAS-STING signal channel can be activated, dendritic cell maturation, macrophage M1 polarization and T cell infiltration are promoted, and the immunosuppression state in TME is counteracted. In addition, the GMCN-coated PEG also has an MR-CT bimodal imaging enhancement function, and integration of diagnosis and treatment is realized. The nano sensitizer disclosed by the invention has huge potential in the aspects of improving the radiotherapy curative effect, remodeling the tumor microenvironment, promoting the anti-tumor immunity, enhancing the biomedical imaging and the like.

The invention relates to a construction method and application of a recombinant oncolytic virus VSV-sPD1IL15RaIL15. The recombinant oncolytic virus VSV-sPD1IL15RaIL15 is constructed by using homologous recombination, and the recombinant oncolytic virus VSV-sPD1IL15RaIL15 can be used for preparing the recombinant oncolytic virus. The preparation method comprises the following steps: firstly designing sPD1 and IL15RaIL15, then fusing the sPD1 and the IL15RaIL15, synthesizing a sPD1IL15RaIL15 gene, amplifying the sPD1IL15RaIL15 gene, inserting the sPD1IL15RaIL15 gene into an ATU region of a VSV whole genome cDNA cloning plasmid pT7-VSV by using a homologous recombination method to obtain a virus whole genome plasmid pT7-VSV-sPD1IL15RaIL15, and co-transfecting the virus whole genome plasmid pT7-VSV-sPD1IL15RaIL15 and an auxiliary plasmid to a 293T cell to prepare the VSV-sPD1IL15RaIL15 oncolytic virus. According to the oncolytic virus, specific anti-tumor immunity is activated, and sPD1IL15RaIL15 is locally expressed in a tumor, so that a long-acting anti-tumor immune response is generated. When the oncolytic virus is used for treating solid tumors, the functions of tumor specific immune cells in a tumor microenvironment can be improved, infiltration of CD8 + T cells and NK cells can be promoted, and the lifetime of tumor-bearing mice can be remarkably prolonged.

The invention relates to the technical field of data management, and discloses a data management platform and management method for tumor immunoassay. The method comprises the following steps: performing standardized acquisition and preprocessing on multi-source tumor immune data to obtain a standardized data set; performing wavelet decomposition and dimension reduction processing on the standardized data set to obtain a dimension reduction feature set; performing cross-center data calibration on the dimension reduction feature set to obtain a calibrated merged data set; performing annotation expansion on the calibrated merged data set to obtain a complete annotation data set; and performing immune feature weight calculation and hierarchical data management according to the complete annotation data set, and generating a hierarchical tumor immune data management structure with differentiated storage priorities. The method is different from a traditional unified storage mode, the heterogeneity of the tumor immune microenvironment is considered, differentiated storage priorities are distributed according to the immune value of the sample, and the computing resource distribution and data access efficiency is optimized.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating lung cancer and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: lily, radix ophiopogonis, thunberg fritillary bulb, astragalus membranaceus, curcuma zedoary, lychee seed, poria cocos, radix scrophulariae, rhizoma anemarrhenae and loofah sponge. The traditional Chinese medicine composition has the effects of tonifying qi and yin, reducing phlegm and resolving masses, and is particularly suitable for treating a patient suffering from qi-yin deficiency and blood stasis type small cell lung cancer. The traditional Chinese medicine composition disclosed by the invention has the effects of reducing tumor cell proliferation, regulating tumor immunity, reducing toxicity and enhancing efficacy, and can also enhance the immunity of a patient, prolong the lifetime of the patient and improve the living quality of the patient.

The invention discloses a cell culture device for anti-tumor immunity, and belongs to the technical field of immune cell culture.The cell culture device comprises a culture box, a base is fixedly connected to the lower surface of the culture box, a cover plate is hinged to the upper surface of the culture box, and a motor is connected to the outer wall of the rear side of the culture box through bolts; a material box is connected to the outer wall of the front side of the culture box through bolts; a long plate is movably connected to the interior of the incubator, and a connecting plate is fixedly connected to the upper surface of the long plate. According to the cell culture device for anti-tumor immunity, when a test tube needs to be clamped, a movable plate is firstly stirred to enable a long pin to stretch a torsion spring, then the test tube is placed in a placement groove, after the movable plate is slowly loosened, the movable plate and a limiting plate are close to the test tube under the action of the torsion spring, and at the moment, the limiting plate drives a rolling ball to rotate in the movable plate; the limiting plates are always in a vertical state, finally the limiting plates on the two sides abut against and clamp the test tube, the operation process is rapid and convenient, the working efficiency is high, and the clamping effect is good.

The invention provides methods to modulate hypoxia-mediated tumor immunity by administration of an O2 carrier polypeptide (e.g., an H-NOX protein). The methods of the invention target both hypoxia inducible factor 1 alpha (HIF-1α) pathways and non-HIF-1α pathways of tumor immunity. Such methods are useful in the treatment of a wide variety of cancers and may be used alone or in combination with other anti-cancer therapies.

The invention belongs to the technical field of cellular immunity, and relates to a non-virus-dependent engineering induced pluripotent stem cell as well as a preparation method and application thereof. A coding gene of a chimeric antigen receptor is inserted into an SIRPA gene on a genome of the engineered induced pluripotent stem cell. According to the invention, iPSC cells are edited in a SIRPA gene position fixed-point insertion mode, simultaneous knockout of SIRPA and integration of an exogenous chimeric antigen receptor CAR are realized, and CAR-iMac can be further induced and differentiated, so that CAR-iMac is differentiated to mononuclear / macrophage tumor targeted cells, the phagocytic ability of CAR-iMac is enhanced, tumor antigens are further presented, the tumor immune microenvironment is improved, and the anti-tumor immunity is enhanced; the method effectively solves the corresponding problem of directly extracting the natural macrophages from the human body, reduces the production cost and the time cost, is beneficial to clinical application, and in addition, utilizes a non-virus-mediated gene editing means to remarkably improve the genetic silencing phenomenon.

The invention discloses a telomerase inhibitor and application thereof, and belongs to the technical field of medicinal chemistry, and the telomerase inhibitor is a compound as shown in a general formula I and pharmaceutically acceptable salt, ester or deuterated substance thereof. The invention also discloses a pharmaceutical composition containing the compound as shown in the general formula I, and application of the pharmaceutical composition and the compound as shown in the general formula I in preparation of antitumor drugs. The telomerase inhibitor and the telomerase inhibitor composition are suitable for promoting permeation of immune cells to tumor tissues and inducing immune exposure of the tumor tissues, so that the anti-tumor immunocompetence of an organism is improved or the curative effect of other anti-tumor immunotherapy is enhanced.

The invention discloses a marker for predicting the curative effect of tumor immunotherapy as well as application and a detection method of the marker, and belongs to the technical field of biomedicine. The marker is glycerophosphorylcholine (GPC) in peripheral blood, and under the condition that the GPC level of peripheral plasma is low, it is judged that ICIs immunotherapy is poor in curative effect response. Peripheral blood samples are simple and noninvasive to obtain, longitudinal curative effect monitoring can be realized, the method is independent of tissue biopsy and is not influenced by tumor heterogeneity, the cost is reduced, and application is facilitated; meanwhile, peripheral blood not only objectively reflects the systematic immune state of a host, but also is closely related to tumor immunity as an important ring in a tumor immune cycle, and in the aspect of accuracy, the efficiency of a prediction model constructed by GPC reaches 0.886 and is remarkably higher than that of PDL1.

The invention discloses a multivalent lysosome targeting chimera and application thereof in protein degradation and immunotherapy, and belongs to the technical field of immunotherapy. The multivalent lysosome targeting chimera provided by the invention can efficiently recognize and combine a target protein and a lysosome shuttle receptor to cause degradation of the target protein through a lysosome way. The lysosome targeting chimera can continuously act at a target part, achieves the beneficial effects of low dosage and high curative effect, can effectively block a PDL1 / PD1 signal axis, causes tumor cell immunogenic death, induces strong anti-tumor immune response, and has multiple effects of inducing tumor apoptosis and blocking immune checkpoints.

The invention discloses a protein variant combination for improving the immune function of iNKT cells and application, and relates to the technical field of tumor immunity. Comprising a protein variant combination consisting of a protein variant ANT A3, a protein variant GLUT3G1, a protein variant LDHB B2, a protein variant PC P4 and a protein variant PCK1K2; according to the invention, gene sequences of the five protein variants are simultaneously embedded into an iNKT cell genome in a fixed-point manner for the first time to form a metabolic reconstitution MetaR-iNKT cell, and it is found that when the MetaR-iNKT cell and an ATP mitochondrial transporter protein inhibitor PENAO are combined for use, lung cancer solid tumors can be synergistically and better killed.

The invention discloses a ternary carrier-free nanoparticle as well as a preparation method and application thereof. The ternary carrier-free nanoparticles comprise nanoparticles which are formed by the chlorine e6, the lonidamine and the RG108 through an intermolecular interaction force. The nanoparticles can improve effective absorption and accumulation of drugs in tumors, can induce tumor specific pyroptosis and immunogenic effect under laser irradiation, and can promote maturation of antigen presenting cells and recruitment and activation of cytotoxic T lymphocytes, thereby starting adaptive anti-tumor immunity.

The invention discloses a method for enhancing the immune function of bone marrow precursor cells by using a 33-site monoubiquitin molecule, and relates to the field of genetic engineering technology. Bone marrow precursor cells BMPCs (Bone Marrow Precursor Cells) are isolated from mouse bone marrow, and the bone marrow precursor cells are pretreated with a 33-site monoubiquitin molecule, and then adoptively immunized in vitro, and finally subjected to enzyme-linked immunosorbent assay and flow cytometry experiments. The experiment shows that the immune function of the treated bone marrow precursor cells is significantly enhanced, and their antigen-specific CTL induction ability is also enhanced, and their ability to kill tumor cells is enhanced; the 33-site monoubiquitin molecule can increase the ability of bone marrow precursor cells to transfer intracellular lymphocytes to produce perforin and granzyme B. Bone marrow precursor cells enhanced by the 33-site monoubiquitin molecule can be used in the preparation of tumor immunotherapy drugs.

The present application relates to cancer immunotherapy, such as T cell stimulation-mediated anti-tumor therapy.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

The present invention discloses a metal complex tailed with an immunologically active molecule, as well as its preparation method and application. The metal complex tailed with an immunologically active molecule exhibits significant anticancer activity. On the one hand, the metal complex exerts cytotoxicity against rapidly growing cancer cells through its active ingredient with anti-tumor immune efficacy. On the other hand, it can also induce immunogenic cell death, enabling the host immune system to attack tumor cells and induce a tumor-specific immune response. (The metal complex of the present invention has been shown to effectively induce immunogenic cell death in non-small cell lung cancer cells and successfully activate anti-tumor immunity in mice in vaccine experiments.) Therefore, the metal complex of the present invention has outstanding effects in anti-cancer, anti-inflammatory, inducing immunogenic cell death, and achieving anti-tumor immunity, and has broad application prospects.

The invention belongs to the technical field of polypeptide conjugate drugs, and particularly relates to a polypeptide conjugate of a Sting small molecule agonist and application of the polypeptide conjugate, and the structural formula of the polypeptide conjugate is shown as the following formula: E-P-L1-L2-L3-L4-L5-D. The polypeptide conjugate of the Sting small molecule agonist has the beneficial effects that the polypeptide conjugate of the Sting small molecule agonist can block the activity of the Sting small molecule agonist, and the polypeptide conjugate can be activated by Legumain highly expressed by tumor cells and tumor-related macrophages in a tumor slightly acidic microenvironment, so that a medicine is selectively released in the tumor microenvironment; the compound has the functions of inhibiting tumor growth, inducing immunogenic death of tumor cells and stimulating anti-tumor immunity of a body, reduces the toxic and side effects of the Sting small-molecule agonist, has good targeting property, and achieves multiple effects of inhibiting tumor growth, promoting anti-tumor immunity and reducing the toxic and side effects of drugs.

The application discloses a lanthanide rare earth nano probe and a preparation method and application thereof, the probe is RENPs, the RENPs take NaNdF4:Yb@NaLuF4 as an imaging element, and the plerixafor is a targeting element.The application provides a lanthanide rare earth nano probe and a preparation method and application thereof, takes NaNdF4:Yb@NaLuF4 as an imaging element, and the small-molecule drug plerixafor is a targeting element, both are combined radiotherapy sensitization elements, a rare earth nano probe RENPs with good biocompatibility and stable NIR-Ⅱ luminescence is constructed, the probe can visualize breast cancer before radiotherapy, so that precise radiotherapy target delineation can be carried out, the sensitivity of tumor cells to radiation is improved during radiotherapy, so that the sensitivity of radiotherapy is improved, the anti-tumor immunity of the body is activated, and the treatment of the anti-PD-L1 immune checkpoint inhibitor in combination can effectively improve the immunotherapy responsiveness, and the prognosis of metastatic and recurrent triple-negative breast cancer patients who lose the opportunity of surgery is improved.

The invention provides methods to modulate hypoxia-mediated tumor immunity by administration of an O2 carrier polypeptide (eg., an H-NOX protein). The methods of the invention target both hypoxia inducible factor 1 alpha (HIF-1α) pathways and non-HIF-1α pathways of tumor immunity. Such methods are useful in the treatment of a wide variety of cancers and may be used alone or in combination with other anti-cancer therapies.

Provided are a CCR8-targeting antibody or an antigen-binding fragment thereof, and an application thereof. The antibody targeting CCR8 or the antigen binding fragment of the antibody is specifically bound with CCR8. The invention further provides application of the antibody in blocking a signal channel for binding / inducing CCR1 and CCR8, clearing CCR8 positive Treg cells through ADCC action and enhancing anti-tumor immunity.

Pharmaceutical compositions and therapeutic methods are provided comprising a single-domain antibody consisting of SEQ ID NO:1 and a pharmaceutically acceptable carrier. The antibody inhibits KRAS GTPase activity and inhibits phosphorylation of STAT3. In certain embodiments, inhibition of KRAS results in decreased phosphorylation of ERK1 / 2. The antibody reduces tumor cell surface PD-L1 expression and reduces VEGF production. The antibody crosses the blood-brain barrier following systemic administration and may exhibit sustained biological activity in vivo. Methods are provided for treating KRAS-mutant cancers, including pancreatic cancer and triple negative breast cancer, and for enhancing anti-tumor immunity through reduction of PD-L1 expression.